Minimal residual disease evaluation in acute myeloid leukaemia.

Yin JA; Grimwade D

doi:10.1016/s0140-6736(02)09419-9

Minimal residual disease evaluation in acute myeloid leukaemia.

Yin JA ¹,

Grimwade D

Affiliations

1. University Department of Haematology, Manchester Royal Infirmary, Manchester M13 9WL, UK.
Authors
Yin JA¹
(1 author)

Lancet (London, England), 01 Jul 2002, 360(9327):160-162
https://doi.org/10.1016/s0140-6736(02)09419-9 PMID: 12126839

Review

Abstract

No abstract provided.

Full text links

Read article at publisher's site: https://doi.org/10.1016/s0140-6736(02)09419-9

References

Articles referenced by this article (26)

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A
Blood, (6):2465-2470 1997
MED: 9310499
Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.
San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, Orfao A
Blood, (6):1746-1751 2001
MED: 11535507
Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S
Blood, (12):3948-3952 2000
MED: 11090082
Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.
Yin JA, Tobal K
Br J Haematol, (3):578-590 1999
MED: 10468847
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A
Blood, (7):2322-2333 1998
MED: 9746770
Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.
Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F
Blood, (3):784-789 1998
MED: 9680345
The significance of minimal residual disease in patients with t(15;17).
Grimwade D
Best Pract Res Clin Haematol, (1):137-158 2002
MED: 11987921
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH
Blood, (12):4131-4143 1999
MED: 10361110
Therapy of molecular relapse in acute promyelocytic leukemia.
Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F
Blood, (7):2225-2229 1999
MED: 10498592
Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.
Cassinat B, Zassadowski F, Balitrand N, Barbey C, Rain JD, Fenaux P, Degos L, Vidaud M, Chomienne C
Leukemia, (2):324-328 2000
MED: 10673752

Show 10 more references (10 of 26)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/170590420

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/170590420

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/s0140-6736(02)09419-9

Supporting

Mentioning

Contrasting

Article citations

The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.
Sorror ML
Blood, 141(18):2173-2186, 01 May 2023
Cited by: 3 articles | PMID: 36800564 | PMCID: PMC10273168
Free full text in Europe PMC
Intravenous Vitamin C Administration Improved Blood Cell Counts and Health-Related Quality of Life of Patient with History of Relapsed Acute Myeloid Leukaemia.
Foster MN, Carr AC, Antony A, Peng S, Fitzpatrick MG
Antioxidants (Basel), 7(7):E92, 16 Jul 2018
Cited by: 9 articles | PMID: 30012948 | PMCID: PMC6070822
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Minimal residual disease testing in hematologic malignancies and solid cancer.
Ben Lassoued A, Nivaggioni V, Gabert J
Expert Rev Mol Diagn, 14(6):699-712, 01 Jul 2014
Cited by: 15 articles | PMID: 24938122
Review
Aptamers from cell-based selection for bioanalytical applications.
Tan W, Donovan MJ, Jiang J
Chem Rev, 113(4):2842-2862, 19 Mar 2013
Cited by: 198 articles | PMID: 23509854 | PMCID: PMC5519293
Review Free full text in Europe PMC
Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.
Grubovikj RM, Alavi A, Koppel A, Territo M, Schiller GJ
Cancers (Basel), 4(2):601-617, 20 Jun 2012
Cited by: 12 articles | PMID: 24213327 | PMCID: PMC3712693
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (32) article citations

Search life-sciences literature (45,105,671 articles, preprints and more)

Minimal residual disease evaluation in acute myeloid leukaemia.

Affiliations

Authors

Abstract

Full text links

References

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

The significance of minimal residual disease in patients with t(15;17).

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

Therapy of molecular relapse in acute promyelocytic leukemia.

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Smart citations by scite.ai
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/s0140-6736(02)09419-9

Article citations

The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.

Intravenous Vitamin C Administration Improved Blood Cell Counts and Health-Related Quality of Life of Patient with History of Relapsed Acute Myeloid Leukaemia.

Minimal residual disease testing in hematologic malignancies and solid cancer.

Aptamers from cell-based selection for bioanalytical applications.

Minimal residual disease as a predictive factor for relapse after allogeneic hematopoietic stem cell transplant in adult patients with acute myeloid leukemia in first and second complete remission.

Similar Articles

Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.

Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo.

Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.

[Minimal residual disease. Methodologies and clinical implications].

Partnerships & funding

Similar Articles

Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.
Br J Haematol, 106(3):578-590, 01 Sep 1999

Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo.
Haematologica, 85(5):481-485, 01 May 2000

Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.
Br J Haematol, 164(1):53-60, 01 Jan 2014

[Minimal residual disease. Methodologies and clinical implications].
Sangre (Barc), 44(4):283-290, 01 Aug 1999

Search life-sciences literature (45,105,671 articles, preprints and more)

Minimal residual disease evaluation in acute myeloid leukaemia.

Author information

Affiliations

Authors

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding